Endra Life Sciences . Warrants Stock News

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended September 30, 2021 and provided a business update. Highlights of the third quarter of 2021 and recent weeks include: Patient screening was initiated at the University of Pittsburgh Medical Center (UPMC) while it continues to work through a pandemic-related backlog of MRI procedures. Both the UPM

Stifel Financial Corp purchased a new stake in ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,500 shares of the companys stock, valued at approximately $27,000. Several other hedge funds also recently bought []

ENDRA Life Sciences (NASDAQ:NDRA) is scheduled to release its earnings data after the market closes on Monday, November 15th. Analysts expect ENDRA Life Sciences to post earnings of ($0.07) per share for the quarter. Persons interested in participating in the companys earnings conference call can do so using this link. ENDRA Life Sciences (NASDAQ:NDRA) last []